Cargando…
Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies
Complex cellular targets such as G protein-coupled receptors (GPCRs), ion channels, and other multi-transmembrane proteins represent a significant challenge for therapeutic antibody discovery, primarily because of poor stability of the target protein upon extraction from cell membranes. To assess wh...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188403/ https://www.ncbi.nlm.nih.gov/pubmed/32343620 http://dx.doi.org/10.1080/19420862.2020.1755069 |
_version_ | 1783527305424928768 |
---|---|
author | Scott, Martin J. Jowett, Amanda Orecchia, Martin Ertl, Peter Ouro-Gnao, Larissa Ticehurst, Julia Gower, David Yates, John Poulton, Katie Harris, Carol Mullin, Michael J. Smith, Kathrine J. Lewis, Alan P. Barton, Nick Washburn, Michael L. de Wildt, Ruud |
author_facet | Scott, Martin J. Jowett, Amanda Orecchia, Martin Ertl, Peter Ouro-Gnao, Larissa Ticehurst, Julia Gower, David Yates, John Poulton, Katie Harris, Carol Mullin, Michael J. Smith, Kathrine J. Lewis, Alan P. Barton, Nick Washburn, Michael L. de Wildt, Ruud |
author_sort | Scott, Martin J. |
collection | PubMed |
description | Complex cellular targets such as G protein-coupled receptors (GPCRs), ion channels, and other multi-transmembrane proteins represent a significant challenge for therapeutic antibody discovery, primarily because of poor stability of the target protein upon extraction from cell membranes. To assess whether a limited set of membrane-bound antigen formats could be exploited to identify functional antibodies directed against such targets, we selected a GPCR of therapeutic relevance (CCR1) and identified target binders using an in vitro yeast-based antibody discovery platform (Adimab(TM)) to expedite hit identification. Initially, we compared two different biotinylated antigen formats overexpressing human CCR1 in a ‘scouting’ approach using a subset of the antibody library. Binders were isolated using streptavidin-coated beads, expressed as yeast supernatants, and screened using a high-throughput binding assay and flow cytometry on appropriate cell lines. The most suitable antigen was then selected to isolate target binders using the full library diversity. This approach identified a combined total of 183 mAbs with diverse heavy chain sequences. A subset of clones exhibited high potencies in primary cell chemotaxis assays, with IC(50) values in the low nM/high pM range. To assess the feasibility of any further affinity enhancement, full-length hCCR1 protein was purified, complementary-determining region diversified libraries were constructed from a high and lower affinity mAb, and improved binders were isolated by fluorescence-activated cell sorting selections. A significant affinity enhancement was observed for the lower affinity parental mAb, but not the high affinity mAb. These data exemplify a methodology to generate potent human mAbs for challenging targets rapidly using whole cells as antigen and define a route to the identification of affinity-matured variants if required. |
format | Online Article Text |
id | pubmed-7188403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-71884032020-05-01 Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies Scott, Martin J. Jowett, Amanda Orecchia, Martin Ertl, Peter Ouro-Gnao, Larissa Ticehurst, Julia Gower, David Yates, John Poulton, Katie Harris, Carol Mullin, Michael J. Smith, Kathrine J. Lewis, Alan P. Barton, Nick Washburn, Michael L. de Wildt, Ruud MAbs Report Complex cellular targets such as G protein-coupled receptors (GPCRs), ion channels, and other multi-transmembrane proteins represent a significant challenge for therapeutic antibody discovery, primarily because of poor stability of the target protein upon extraction from cell membranes. To assess whether a limited set of membrane-bound antigen formats could be exploited to identify functional antibodies directed against such targets, we selected a GPCR of therapeutic relevance (CCR1) and identified target binders using an in vitro yeast-based antibody discovery platform (Adimab(TM)) to expedite hit identification. Initially, we compared two different biotinylated antigen formats overexpressing human CCR1 in a ‘scouting’ approach using a subset of the antibody library. Binders were isolated using streptavidin-coated beads, expressed as yeast supernatants, and screened using a high-throughput binding assay and flow cytometry on appropriate cell lines. The most suitable antigen was then selected to isolate target binders using the full library diversity. This approach identified a combined total of 183 mAbs with diverse heavy chain sequences. A subset of clones exhibited high potencies in primary cell chemotaxis assays, with IC(50) values in the low nM/high pM range. To assess the feasibility of any further affinity enhancement, full-length hCCR1 protein was purified, complementary-determining region diversified libraries were constructed from a high and lower affinity mAb, and improved binders were isolated by fluorescence-activated cell sorting selections. A significant affinity enhancement was observed for the lower affinity parental mAb, but not the high affinity mAb. These data exemplify a methodology to generate potent human mAbs for challenging targets rapidly using whole cells as antigen and define a route to the identification of affinity-matured variants if required. Taylor & Francis 2020-04-28 /pmc/articles/PMC7188403/ /pubmed/32343620 http://dx.doi.org/10.1080/19420862.2020.1755069 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Report Scott, Martin J. Jowett, Amanda Orecchia, Martin Ertl, Peter Ouro-Gnao, Larissa Ticehurst, Julia Gower, David Yates, John Poulton, Katie Harris, Carol Mullin, Michael J. Smith, Kathrine J. Lewis, Alan P. Barton, Nick Washburn, Michael L. de Wildt, Ruud Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies |
title | Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies |
title_full | Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies |
title_fullStr | Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies |
title_full_unstemmed | Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies |
title_short | Rapid identification of highly potent human anti-GPCR antagonist monoclonal antibodies |
title_sort | rapid identification of highly potent human anti-gpcr antagonist monoclonal antibodies |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188403/ https://www.ncbi.nlm.nih.gov/pubmed/32343620 http://dx.doi.org/10.1080/19420862.2020.1755069 |
work_keys_str_mv | AT scottmartinj rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT jowettamanda rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT orecchiamartin rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT ertlpeter rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT ourognaolarissa rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT ticehurstjulia rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT gowerdavid rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT yatesjohn rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT poultonkatie rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT harriscarol rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT mullinmichaelj rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT smithkathrinej rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT lewisalanp rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT bartonnick rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT washburnmichaell rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies AT dewildtruud rapididentificationofhighlypotenthumanantigpcrantagonistmonoclonalantibodies |